Financial Survey: Novabridge Biosciences (NBP) vs. The Competition

Novabridge Biosciences (NASDAQ:NBP) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Novabridge Biosciences to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Insider & Institutional Ownership

38.4% of Novabridge Biosciences shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 22.1% of Novabridge Biosciences shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Novabridge Biosciences and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Novabridge Biosciences	N/A	-$46.27 million	-2.53
Novabridge Biosciences Competitors	$742.03 million	$14.11 million	-15.39

Novabridge Biosciences’ peers have higher revenue and earnings than Novabridge Biosciences. Novabridge Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Novabridge Biosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Novabridge Biosciences	N/A	N/A	N/A
Novabridge Biosciences Competitors	-12,346.73%	-197.60%	-30.56%

Analyst Ratings

This is a breakdown of current ratings for Novabridge Biosciences and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novabridge Biosciences	1	0	1	0	2.00
Novabridge Biosciences Competitors	9839	15125	45459	1588	2.54

Novabridge Biosciences presently has a consensus target price of $9.00, indicating a potential upside of 889.01%. As a group, “Biotechnology” companies have a potential upside of 99.59%. Given Novabridge Biosciences’ higher probable upside, equities research analysts clearly believe Novabridge Biosciences is more favorable than its peers.

Volatility and Risk

Novabridge Biosciences has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Novabridge Biosciences’ peers have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Summary

Novabridge Biosciences beats its peers on 7 of the 13 factors compared.

Novabridge Biosciences Company Profile

Novabridge Biosciences, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.